Glofitamab as a single agent in heavily pretreated patients with DLBCL

Glofitamab: a valuable agent for the treatment of patients with R/R mantle cell lymphomaПодробнее

Glofitamab induces durable complete remissions in patients with relapsed large B-cell lymphomaПодробнее

Michael Dickinson, MBBS, DMedSc, on a Phase II Trial of Glofitamab in DLBCLПодробнее

The benefits of glofitamab in R/R DLBCL post-CAR-T therapyПодробнее

A Phase I/II trial of glofitamab monotherapy in R/R MCLПодробнее

COALITION: glofitamab + R-CHOP or glofitamab + pola-R-CHP in high-risk DLBCLПодробнее

Phase II study of glofitamab in patients with R/R LBCLПодробнее

Glofitamab in R/R DLBCL: updated safety and efficacy dataПодробнее

The current and future role of bispecifics in R/R DLBCL: epcoritamab, glofitamab & moreПодробнее

Glofitamab as a SOC in third-line DLBCL and its potential in earlier lines of therapyПодробнее

Glofitamab and polatuzumab vedotin in DLBCLПодробнее

ASH highlights: glofitamab in DLBCL & pirtobrutinib and epcoritamab in Richter's transformationПодробнее

The next generation of novel agents in development for aggressive B-cell lymphomaПодробнее

Efficacy and safety of glofitamab for patients with Richter’s transformationПодробнее

Glofitamab, a CD20/CD3 bispecific antibody, in the treatment of R/R DLBCLПодробнее

Bispecific antibodies in NHL: current insights and ongoing studiesПодробнее

COALITION: glofitamab + R-CHOP or glofitamab + pola-R-CHP in patients with high-risk DLBCLПодробнее

Updated results of glofitamab plus polatuzumab vedotin combination therapy in DLBCL, including HGBCLПодробнее

Updated efficacy data on glofitamab step-up dosing in NHLПодробнее